Research advances of targeted therapy for neuroblastoma in children

References:

[1] Matthay KK, Maris JM, Schleiermacher G, et al.Neuroblastoma[J].Nat Rev Dis Primers, 2016, 2:16078.DOI:10.1038/nrdp.2016.78.
[2] Park JR, Bagatell R, Cohn SL, et al.Revisions to the International Neuroblastoma Response Criteria:a consensus statement from the National Cancer Institute Clinical Trials Planning Meeting[J].J Clin Oncol, 2017, 35(22):2580-2587.DOI:10.1200/JCO.2016.72.0177.
[3] Brodeur GM.Neuroblastoma:biological insights into a clinical enigma[J].Nat Rev Cancer, 2003, 3(3):203-216.DOI:10.1038/nrc1014.
[4] Mossé YP.Anaplastic lymphoma kinase as a cancer target in pediatric malignancies[J].Clin Cancer Res, 2016, 22(3):546-552.DOI:10.1158/1078-0432.CCR-14-1100.
[5] Cheung NKV, Dyer MA.Neuroblastoma:developmental biology, cancer genomics and immunotherapy[J].Nat Rev Cancer, 2013, 13(6):397-411.DOI:10.1038/nrc3526.
[6] Yu AL, Gilman AL, Ozkaynak MF, et al.Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma[J].N Engl J Med, 2010, 363(14):1324-1334.DOI:10.1056/NEJMoa0911123.
[7] Pugh TJ, Morozova O, Attiyeh EF, et al.The genetic landscape of high-risk neuroblastoma[J].Nat Genet, 2013, 45(3):279-284.DOI:10.1038/ng.2529.
[8] Suzuki M, Cheung NKV.Disialoganglioside GD2 as a therapeutic target for human diseases[J].Expert Opin Ther Targets, 2015, 19(3):349-362.DOI:10.1517/14728222.2014.986459.
[9] Yu AL, Gilman AL, Ozkaynak MF, et al.Long-term follow-up of a phase III study of ch14.18(dinutuximab) + cytokine immunotherapy in children with high-risk neuroblastoma:COG study ANBL0032[J].Clin Cancer Res, 2021, 27(8):2179-2189.DOI:10.1158/1078-0432.CCR-20-3909.
[10] Mody R, Naranjo A, Van Ryn C, et al.Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221):an open-label, randomised, phase 2 trial[J].Lancet Oncol, 2017, 18(7):946-957.DOI:10.1016/S1470-2045(17)30355-8.
[11] Shusterman S, London WB, Gillies SD, et al.Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma:a Children’s Oncology Group (COG) phase II study[J].J Clin Oncol, 2010, 28(33):4969-4975.DOI:10.1200/JCO.2009.27.8861.
[12] González A, González-González A, Alonso-González C, et al.Melatonin inhibits angiogenesis in SH-SY5Y human neuroblastoma cells by downregulation of VEGF[J].Oncol Rep, 2017, 37(4):2433-2440.DOI:10.3892/or.2017.5446.
[13] Modak S, Kushner BH, Basu E, et al.Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma:results of a phase II study[J].Pediatr Blood Cancer, 2017, 64(8):e26448.DOI:10.1002/pbc.26448.
[14] Calafiore L, Amoroso L, Della Casa Alberighi O, et al.Two-stage phase II study of imatinib mesylate in subjects with refractory or relapsing neuroblastoma[J].Ann Oncol, 2013, 24(5):1406-1413.DOI:10.1093/annonc/mds648.
[15] Henssen A, Althoff K, Odersky A, et al.Targeting MYCN-driven transcription by BET-bromodomain inhibition[J].Clin Cancer Res, 2016, 22(10):2470-2481.DOI:10.1158/1078-0432.CCR-15-1449.
[16] Delmore JE, Issa GC, Lemieux ME, et al.BET bromodomain inhibition as a therapeutic strategy to target c-Myc[J].Cell, 2011, 146(6):904-917.DOI:10.1016/j.cell.2011.08.017.
[17] Sauvage D, Bosseler M, Viry E, et al.The BET protein inhibitor JQ1 decreases hypoxia and improves the therapeutic benefit of anti-PD-1 in a high-risk neuroblastoma mouse model[J].Cells, 2022, 11(18):2783.DOI:10.3390/cells11182783.
[18] DuBois SG, Marachelian A, Fox E, et al.Phase I study of the Aurora a kinase inhibitor alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma:a NANT (new approaches to neuroblastoma therapy) trial[J].J Clin Oncol, 2016, 34(12):1368-1375.DOI:10.1200/JCO.2015.65.4889.
[19] Seto E, Yoshida M.Erasers of histone acetylation:the histone deacetylase enzymes[J].Cold Spring Harb Perspect Biol, 2014, 6(4):a018713.DOI:10.1101/cshperspect.a018713.
[20] Cheung BB, Kleynhans A, Mittra R, et al.A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma[J].Oncogene, 2021, 40(13):2367-2381.DOI:10.1038/s41388-021-01712-w.
[21] Waldeck K, Cullinane C, Ardley K, et al.Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model[J].Int J Cancer, 2016, 139(1):194-204.DOI:10.1002/ijc.30056.
[22] Chava S, Reynolds CP, Pathania AS, et al.miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma[J].Mol Oncol, 2020, 14(1):180-196.DOI:10.1002/1878-0261.12588.
[23] Trigg RM, Turner SD.ALK in neuroblastoma:biological and therapeutic implications[J].Cancers (Basel), 2018, 10(4):113.DOI:10.3390/cancers10040113.
[24] Hallberg B, Palmer RH.The role of the ALK receptor in cancer biology[J].Ann Oncol, 2016, 27(Suppl 3):iii4-iii15.DOI:10.1093/annonc/mdw301.
[25] Schulte JH, Schulte S, Heukamp LC, et al.Targeted therapy for neuroblastoma:ALK inhibitors[J].Klin Padiatr, 2013, 225(6):303-308.DOI:10.1055/s-0033-1357132.
[26] Foster JH, Voss SD, Hall DC, et al.Activity of crizotinib in patients with ALK-aberrant relapsed/refractory neuroblastoma:a children’s oncology group study (ADVL0912)[J].Clin Cancer Res, 2021, 27(13):3543-3548.DOI:10.1158/1078-0432.CCR-20-4224.
[27] Cervantes-Madrid D, Szydzik J, Lind DE, et al.Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells[J].Sci Rep, 2019, 9(1):19353.DOI:10.1038/s41598-019-55060-7.
[28] Fischer M, Moreno L, Ziegler DS, et al.Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies:an open-label, multicentre, phase 1, dose-escalation and dose-expansion study[J].Lancet Oncol, 2021, 22(12):1764-1776.DOI:10.1016/S1470-2045(21)00536-2.
[29] Redaelli S, Ceccon M, Zappa M, et al.Lorlatinib treatment elicits multiple on-and off-target mechanisms of resistance in ALK-driven cancer[J].Cancer Res, 2018, 78(24):6866-6880.DOI:10.1158/0008-5472.CAN-18-1867.
[30] O’Donohue TJ, Ibá?ez G, Coutinho DF, et al.Translational strategies for repotrectinib in neuroblastoma[J].Mol Cancer Ther, 2021, 20(11):2189-2197.DOI:10.1158/1535-7163.MCT-21-0126.
[31] Morgenstern DA, Marzouki M, Bartels U, et al.Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors[J].Pediatr Blood Cancer, 2014, 61(1):128-133.DOI:10.1002/pbc.24656.
[32] Fulda S.The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma[J].Curr Cancer Drug Targets, 2009, 9(6):729-737.DOI:10.2174/156800909789271521.
[33] Chilamakuri R, Agarwal S.Dual targeting of PI3K and HDAC by CUDC-907 inhibits pediatric neuroblastoma growth[J].Cancers (Basel), 2022, 14(4):1067.DOI:10.3390/cancers14041067.
[34] Mlakar V, Morel E, Mlakar SJ, et al.A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma[J].J Exp Clin Cancer Res, 2021, 40(1):189.DOI:10.1186/s13046-021-01967-x.
[35] Yu XY, Fan HJ, Jiang XR, et al.Apatinib induces apoptosis and autophagy via the PI3K/AKT/mTOR and MAPK/ERK signaling pathways in neuroblastoma[J].Oncol Lett, 2020, 20(4):52.DOI:10.3892/ol.2020.11913.
[36] Wang HW, Wang XR, Xu LP, et al.TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma[J].BMC Genom Data, 2022, 23(1):41.DOI:10.1186/s12863-022-01059-5.
[37] Bhoopathi P, Gorantla B, Sailaja GS, et al.Retraction:SPARC overexpression inhibits cell proliferation in neuroblastoma and is partly mediated by tumor suppressor protein PTEN and AKT[J].PLoS One, 2020, 15(1):e0228246.DOI:10.1371/journal.pone.0228246.
[38] Lamers F, Schild L, den Hartog IJM, et al.Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth[J].Eur J Cancer, 2012, 48(16):3093-3103.DOI:10.1016/j.ejca.2012.01.037.
[39] Tsai HC, Li HL, Van Neste L, et al.Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells[J].Cancer Cell, 2012, 21(3):430-446.DOI:10.1016/j.ccr.2011.12.029.
[40] Lin HY, Chuang JH, Wang PW, et al.5-aza-2’-deoxycytidine induces a RIG-I-related innate immune response by modulating mitochondria stress in neuroblastoma[J].Cells, 2020, 9(9):1920.DOI:10.3390/cells9091920.
[41] Li ZP, Chen HJ.miR-34a inhibits proliferation, migration and invasion of paediatric neuroblastoma cells via targeting HNF4α[J].Artif Cells Nanomed Biotechnol, 2019, 47(1):3072-3078.DOI:10.1080/21691401.2019.1637886.
[42] Baranowska-Kortylewicz J, Kortylewicz ZP, McIntyre EM, et al.Multifarious functions of butyrylcholinesterase in neuroblastoma:impact of BCHE deletion on the neuroblastoma growth in vitro and in vivo[J].J Pediatr Hematol Oncol, 2022, 44(6):293-304.DOI:10.1097/MPH.0000000000002285.
[43] Louis CU, Savoldo B, Dotti G, et al.Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma[J].Blood, 2011, 118(23):6050-6056.DOI:10.1182/blood-2011-05-354449.
[44] Kendsersky NM, Lindsay J, Kolb EA, et al.The B7-H3-targeting antibody-drug conjugate m276-SL-PBD is potently effective against pediatric cancer preclinical solid tumor models[J].Clin Cancer Res, 2021, 27(10):2938-2946.DOI:10.1158/1078-0432.CCR-20-4221.
[45] Chatterjee N, Bivona TG.Polytherapy and targeted cancer drug resistance[J].Trends Cancer, 2019, 5(3):170-182.DOI:10.1016/j.trecan.2019.02.003.